PT  - JOURNAL ARTICLE
AU  - S. Kim
AU  - L.A. Loevner
AU  - H. Quon
AU  - A. Kilger
AU  - E. Sherman
AU  - G. Weinstein
AU  - A. Chalian
AU  - H. Poptani
TI  - Prediction of Response to Chemoradiation Therapy in Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging
AID  - 10.3174/ajnr.A1817
DP  - 2010 Feb 01
TA  - American Journal of Neuroradiology
PG  - 262--268
VI  - 31
IP  - 2
4099  - http://www.ajnr.org/content/31/2/262.short
4100  - http://www.ajnr.org/content/31/2/262.full
SO  - Am. J. Neuroradiol.2010 Feb 01; 31
AB  - BACKGROUND AND PURPOSE: Tumor microenvironment, including blood flow and permeability, may provide crucial information regarding response to chemoradiation therapy. Thus, the objective of this study was to investigate the efficacy of pretreatment DCE-MR imaging for prediction of response to chemoradiation therapy in HNSCC. MATERIALS AND METHODS: DCE-MR imaging studies were performed on 33 patients with newly diagnosed HNSCC before neoadjuvant chemoradiation therapy by using a 1.5T (n = 24) or a 3T (n = 9) magnet. The data were analyzed by using SSM for estimation of Ktrans, ve, and τi. Response to treatment was determined on completion of chemoradiation as CR, with no evidence of disease (clinically or pathologically), or PR, with pathologically proved residual tumor. RESULTS: The average pretreatment Ktrans value of the CR group (0.64 ± 0.11 minutes−1, n = 24) was significantly higher (P = .001) than that of the PR (0.21 ± 0.05 minutes−1, n = 9) group. No significant difference was found in other pharmacokinetic model parameters: ve and τi, between the 2 groups. Although the PR group had larger metastatic nodal volume than the CR group, it was not significantly different (P = .276). CONCLUSIONS: These results indicate that pretreatment DCE-MR imaging can be potentially used for prediction of response to chemoradiation therapy of HNSCC. AIFarterial input functionCEcontrast-enhancedchemochemotherapyCMcetuximabConc. Chemoconcurrent chemotherapyCPcisplatinCRcomplete responseDCEdynamic contrast-enhancedDMdistant metastasisDTdocetaxolEGFRepidermal growth factor receptor5FU5-fluorouracilGd-DTPAgadolinium diethylene triamine pentaacetic acidGKMgeneral kinetic modelHNSCChead and neck squamous cell carcinomasimmunoimmunotherapyInd. Chemoinduction chemotherapyKtranstransfer constant6MFU6-month follow-upNnegativeNEDno evidence of diseasePpositivePRpartial responseRstreatment responseSgsurgeryPapathologySSMshutter speed modelT1WIT1-weighted imagingT2WIT2-weighted imagingTXTaxolve,extravascular extracellular space volume fractionτi,intracellular water lifetimeYyes